

EQA round: IGIT1/23 - Immunopathology of GIT

Deadline: 13.3.2023

Setup: groups - measurement principle

AV = assigned value

N_{tot} = total number of the resultsN_{eva} = number of the results assessed

CVP = consensus of all participants

N_{rel} = relative number of the resultsN_{suc} = number of successful results

>>> ... expected result

S_{rel} = relative success

> ... acceptable result

± ... result not assessed

Test Sample Group	Frequency of the results					Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]	
Set 1								
(595) anti-gliadin IgA (deamidated)		72				72	72	100
Sample A1		72				72	72	100
(1) Fluorescent methods	CVP >>>	1	1,4	Positive				
(2) EIA methods	CVP >>>	60	83	Positive				
(5) LIA, ILMA	CVP >>>	9	13	Positive				
(99) Another measurement principle	CVP >>>	2	2,8	Positive				
Sample B1		72				72	72	100
(1) Fluorescent methods	CVP >>>	1	1,4	Negative				
(2) EIA methods	CVP >>>	60	83	Negative				
(5) LIA, ILMA	CVP >>>	9	13	Negative				
(99) Another measurement principle	CVP >>>	2	2,8	Negative				
(594) anti-gliadin IgG (deamidated)		75				75	73	97
Sample A1		75				75	73	97
(1) Fluorescent methods	CVP >>>	1	1,3	Positive				
(2) EIA methods		1	1,3	Negative				
	CVP >>>	60	80	Positive				
(5) LIA, ILMA	CVP >>>	10	13	Positive				
(99) Another measurement principle		1	1,3	Negative				
	CVP >>>	2	2,7	Positive				
Sample B1		75				75	74	99
(1) Fluorescent methods	CVP >>>	1	1,3	Negative				
(2) EIA methods	CVP >>>	60	80	Negative				
		1	1,3	Positive				
(5) LIA, ILMA	CVP >>>	10	13	Negative				
(99) Another measurement principle	CVP >>>	3	4	Negative				
(421) anti-gliadin IgA (native)		18				18	18	100
Sample A1		18				18	18	100
(2) EIA methods	CVP >>>	18	100	Positive				
Sample B1		18				18	18	100
(2) EIA methods	CVP >>>	18	100	Negative				
(420) anti-gliadin IgG (native)		18				18	18	100
Sample A1		18				18	18	100
(2) EIA methods	CVP >>>	18	100	Positive				
Sample B1		18				18	18	100
(2) EIA methods	CVP >>>	18	100	Negative				
Set 2								
(424) anti-endomysium IgA		73				73	73	100
Sample A2		73				73	73	100
(1) Fluorescent methods	CVP >>>	72	99	Negative				
(2) EIA methods	CVP >>>	1	1,4	Negative				
Sample B2		73				73	73	100
(1) Fluorescent methods	CVP >>>	72	99	Positive				
(2) EIA methods	CVP >>>	1	1,4	Positive				
(425) anti-transglutaminase IgA		85				85	84	99
Sample A2		85				85	84	99
(1) Fluorescent methods	CVP >>>	1	1,2	Negative				
(2) EIA methods	CVP >>>	64	75	Negative				
		1	1,2	Positive				
(5) LIA, ILMA	CVP >>>	17	20	Negative				
(99) Another measurement principle	CVP >>>	2	2,4	Negative				
Sample B2		85				85	85	100
(1) Fluorescent methods	CVP >>>	1	1,2	Positive				
(2) EIA methods	CVP >>>	65	76	Positive				
(5) LIA, ILMA	CVP >>>	17	20	Positive				
(99) Another measurement principle	CVP >>>	2	2,4	Positive				
Set 3								
(592) anti-Saccharomyces cerevisiae IgA		66				66	66	100
Sample A3		66				66	66	100
(1) Fluorescent methods	CVP >>>	23	35	Positive				
(2) EIA methods	CVP >>>	41	62	Positive				
(5) LIA, ILMA	CVP >>>	1	1,5	Positive				

EQA round: IGIT1/23 - Immunopathology of GIT

Deadline: 13.3.2023

Setup: groups - measurement principle

Test Sample Group	AV	N _{tot}	Frequency of the results		Success		
			N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]
(99) Another measurement principle	CVP >>>	1	1,5	Positive			
Sample B3		66			66	66	100
(1) Fluorescent methods	CVP >>>	23	35	Negative			
(2) EIA methods	CVP >>>	41	62	Negative			
(5) LIA, ILMA	CVP >>>	1	1,5	Negative			
(99) Another measurement principle	CVP >>>	1	1,5	Negative			
(593) anti-Saccharomyces cerevisiae IgG		59			59	59	100
Sample A3		59			59	59	100
(1) Fluorescent methods	CVP >>>	20	34	Positive			
(2) EIA methods	CVP >>>	37	63	Positive			
(5) LIA, ILMA	CVP >>>	1	1,7	Positive			
(99) Another measurement principle	CVP >>>	1	1,7	Positive			
Sample B3		59			59	59	100
(1) Fluorescent methods	CVP >>>	20	34	Negative			
(2) EIA methods	CVP >>>	37	63	Negative			
(5) LIA, ILMA	CVP >>>	1	1,7	Negative			
(99) Another measurement principle	CVP >>>	1	1,7	Negative			